Fabimycin Antibiotic Accumulation in Gram-Negative Bacteria

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of novel antibiotics effective against Gram-negative ESKAPE pathogens due to their dense lipopolysaccharide outer membrane and efflux pumps preventing antibiotic accumulation, leading to increased mortality from drug-resistant infections.

Innovation Solution

Development of fabimycin, a FabI inhibitor with enhanced antibacterial potency and decreased toxicity, designed to accumulate within Gram-negative bacteria, using iterative compound synthesis and x-ray crystallography to target the enoyl-acyl carrier reductase enzyme, effectively inhibiting bacterial fatty acid biosynthesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If traditional antibiotics are used against Gram-negative pathogens, then they can target bacterial enzymes, but they cannot accumulate inside the bacteria due to the dense lipopolysaccharide outer membrane and efflux pumps

Engineering Contradiction:

Improveantibiotic accumulation inside bacteriaVSAvoidouter membrane barrier and efflux pumps

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the physicochemical parameters of the antibiotic molecule (Debio-1452) by adding a basic amine group, changing its charge properties and membrane permeability characteristics. This parameter change enables the compound to accumulate inside Gram-negative bacteria despite the presence of efflux pumps and outer membrane barriers.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent exploits the promiscuous efflux pumps that normally expel antibiotics as a beneficial mechanism by designing a compound (Debio-1452-NH3) that is actively pumped into the cell. The efflux pumps, which are harmful against traditional antibiotics, become the delivery mechanism for the modified compound, converting a harmful factor into a benefit.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If Debio-1452 is used to inhibit FabI enzyme, then it can block fatty acid biosynthesis, but it does not accumulate inside Gram-negative bacteria and is therefore inactive

Engineering Contradiction:

ImproveFabI inhibition activityVSAvoidintracellular concentration of Debio-1452

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the chemical structure of Debio-1452 by adding a basic amine group (NH3), which fundamentally alters its transport properties across the bacterial outer membrane. This structural parameter change maintains FabI inhibition capability while enabling active accumulation inside Gram-negative bacteria through efflux pump-mediated uptake.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If high-throughput screens of millions of compounds are performed, then diverse compounds can be tested, but they fail to identify Gram-negative active antibiotics because accumulating compounds possess specific physicochemical properties

Engineering Contradiction:

Improvescreening throughputVSAvoididentification of Gram-negative active compounds

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

Instead of relying on high-throughput screening to discover compounds with the right properties, the patent takes preliminary action by deliberately designing and synthesizing compounds with known favorable physicochemical properties (basic amine groups) that predict accumulation in Gram-negative bacteria. This targeted approach bypasses the need for extensive screening while ensuring the desired accumulation behavior.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Fabimycin demonstrates significant antibacterial activity against >200 clinical isolates of E. coli, K. pneumoniae, and A. baumannii, showing improved potency and tolerability in mouse infection models, including urinary tract infections, and maintains efficacy in challenging infection scenarios.

Implementation Method 1

target the enoyl-acyl carrier reductase enzyme FabI, which catalyzes the key rate-determining step in bacterial fatty acid biosynthesis

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 2

use of iterative compound synthesis, clinical isolate testing, and x-ray crystallography to identify fabimycin

Methodology Applied

Scientific EffectX-ray diffraction: X-Ray

Data Source

PatentUS20240190872A1Fabi inhibitors for gram-negative pathogens

Publication Date: 2024.06.13 THE GENERAL HOSPITAL CORP

AI summary

A FabI inhibitor called fabimycin that has impressive activity against >200 clinical isolates of E. coli, K. pneumoniae, and A. baumannii. Fabimycin has activity in multiple mouse models of infection caused by Gram-negative bacteria, including a model of urinary tract infection. Fabimycin has translational promise, and its discovery provides data indicating that antibiotics whose spectrum of activity is restricted to Gram-positive bacteria can be systematically modified to accumulate in Gram-negative bacteria and be effective against these problematic pathogens.